VentureBeat

TODAY’S HEADLINES:

• Oxford NanoLabs takes in £10M for sequencing tech (PDF release)
• Alure Medical raises $4.5M for plastic-surgery implants (release)
• Bone-disease biotech Therosteon spins out of research institute, raises funds (PDF release)
• Genome-analysis toolmaker BioTrove files for $75M IPO (Edgar)
• RNAi developer Tekmira acquires Protiva, ends litigation (release)

Oxford NanoLabs takes in £10M for sequencing tech – U.K. based Oxford NanoLabs, yet another startup developing high-speed genome-sequencing technology, raised £10 million in a new funding round. The company said only that its backers included institutional and private investors.

Oxford is working on a so-called nanopore technique for DNA analysis, which typically involves chips laced with a lattice of tiny holes. The company says its process can identify the DNA “letters,” or bases, that compose the genetic code by passing DNA molecules through the pores. As each base slides past, it sticks temporarily to the side of the pore, interrupting electricity being conducted through the surface in a characteristic way that identifies whether the base is an A, C, G or T — the four letters of the DNA alphabet.

Of course, Oxford is entering a field crowded with established companies and other startups. In no particular order, we’ve recently covered fundraising and technology developments at BioNanomatrix, Intelligent Bio-Systems and Pacific Biosciences in recent months.

Alure Medical raises $4.5M for plastic-surgery implants – San Diego’s Alure Medical, a startup developing “soft-tissue” implants for cosmetic procedures, raised $4.5 million in a first funding round. Its backers include EDF Ventures and private investors.

The company is working on implants that lift sagging tissues in the breast, neck and elsewhere. Alure also named France Dixon Helfer, a former Medtronic executive and co-founder of Pegasus Biologics, as its new CEO.